Drug Eluting Balloons will Drug-Eluting Balloons ... - summitMD.com

More documents

Recommendations

Info

Angiographic Out<strong>com</strong>es: PCB Trials for “De Novo” Applications • PEPCAD III: BMS Crimped on PCB (3 µg/mm 2 ) versus Cypher Stent • Lutonix De Novo Registry: Pre or Post Dilatation Using PCB (2 µg/mm 2 ) Angiographic Late Loss (mm) Binary Restenosis (%) PEPCAD III N= 325 0.11 P
Synergistic Use of PCB and BMS Lessons Learned From the PEPCAD Trials • PEPCAD I (SVD): • Binary Restenosis: DEB Only (5.5%) versus DEB+BMS (41.3%) • Stent Thrombosis: DEB Only (0%) versus DEB+BMS (1.7%) • PEPCAD III (De Novo + BMS): • Definite Stent Thrombosis: DEB+BMS (1.3%) versus Cypher (0.3%) • PEPCAD V (28 Patients t Bifurcation Study) • Late Stent Thrombosis Rate (7.1%)
Page 1 and 2: Drug-Eluting Balloons will Have an
Page 3 and 4: Drug Coated Balloon Technologies A
Page 5 and 6: PCB for the Treatment of ISR Angiog
Page 7 and 8: Clinical Outcomes Among 250 Patient
Page 9 and 10: PCB for the Treatment of De Novo SF
Page 11: Vascular Healing Following PCB Use
Page 15 and 16: (1) Systemic Release of Paclitaxel
Page 17 and 18: Deposition of a Drug Delivery Biofi
Page 19 and 20: (3) Local Tissue Effects (Safety) V
Page 21: Conclusions: PCB Technologies • P

Drug Eluting Balloons will Drug-Eluting Balloons ... - summitMD.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?